reports
Apollo Global Management Inc: 1 director
A director at Apollo Global Management Inc sold 8,500 shares at 146.030USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Snap Inc: 1 director
A director at Snap Inc sold 1,259,900 shares at 8.000USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Avalo Therapeutics Announces Inducement Grants to New Employees Under ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as indu...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Re...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechno...
- Dan Salmon
Snap Inc. (SNAP, Neutral, $8 target) Revenue growth in-line, and Perpl...
What’s New: In this first take following tonight’s results, we focus on: 1. Stock pops on improved results and surprise Perplexity deal 2. DR recovers & continued enthusiasm for SMBs, but large advertisers down 3. North America DAUs steady but we remain cautious as age verification rolls out 4. Perplexity boosts the AI narrative 5. Very good cost control and margins
WestCX Launches Engage: Real-Time AI That Speaks, Listens, and Learns ...
WestCX Launches Engage: Real-Time AI That Speaks, Listens, and Learns Across Every Patient Interaction New Engage, LinguaAI, and Journey Insights solutions bring multilingual, measurable, and human-like communication to healthcare organizations OMAHA, Neb., Nov. 04, 2025 (GLOBE NEWSWIRE) -- , part of , today announced the launch of Engage, the next generation of its AI-native engagement platform. The launch unites Engage, LinguaAI, and Journey Insights into a single ecosystem that enables healthcare organizations to deliver intelligent, multilingual, and measurable patient experiences. ...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation ConferenceFireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare ConferenceFireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1st Immunology & Inflamm...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enro...
- Dan Salmon
Snap Inc. (SNAP, Neutral, $8 target) Downgrade to Neutral on lower DR...
We are downgrading SNAP to Neutral from Buy and our target declines to $8 from $11. Direct Response Ad Business Evolving: Our prior Buy thesis was anchored by SNAP’s improved direct response ad offering and was helped by growth of its small advertiser base over the past year-plus. However, DR ad growth faded to +5% in 2Q25 from mid-teens, and our channel checks remain mixed.
WestCX Elevates Pharmacy Operations with New Agentic AI Solution
WestCX Elevates Pharmacy Operations with New Agentic AI Solution Strategic AI for Enhanced Adherence, Efficiency, and Revenue Growth OMAHA, Neb., Oct. 21, 2025 (GLOBE NEWSWIRE) -- , part of the , today announced the launch of its agentic AI solution engineered to optimize pharmacy-patient interactions. The solution enables pharmacies to automate patient communications, improve medication adherence, and reduce operational strain. Available through WestCX’s and brands, it blends conversational AI with agentic capabilities to deliver personalized patient interactions across channels via...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Bu...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Aval...
WestCX Launches Secure Messaging and Dynamic QR Innovation at Becker’s...
WestCX Launches Secure Messaging and Dynamic QR Innovation at Becker’s 2025 New AI-native solutions improve engagement, strengthen revenue, and ensure compliance for healthcare organizations OMAHA, Neb., Sept. 30, 2025 (GLOBE NEWSWIRE) -- WestCX, part of the , today announced the launch of its (RCS) and Dynamic QR capabilities at the (Booth 617). Available through its and brands, these innovations help healthcare providers, payors, and life sciences organizations improve patient engagement, reduce costs, capture more revenue, and meet the strictest compliance standards. Measurable ...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
PCTY PAYLOCITY HOLDING CORP.
LNTH LANTHEUS HOLDINGS INC
HUBS HUBSPOT INC.
HAE HAEMONETICS CORPORATION
CRM SALESFORCE.COM INC.
CRK COMSTOCK RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
AR ANTERO RESOURCES CORPORATION
HRB H&R BLOCK INC.
SNAP SNAP INC. CLASS A
CNX CNX RESOURCES CORPORATION
ACI-R-A ADRIATIC CROATIA INTERNATIONAL CLUB D.D.
HPK HIGHPEAK ENERGY INC (A)
ACVA ACV AUCTIONS INC
CHK CHESAPEAKE ENERGY CORP
BRZE BRAZE INC
SG SWEETGREEN INC
MNDY MONDAY COM LTD
IOT SAMSARA INC
KLC KINDERCARE LEARNING COS INC
TEAM ATLASSIAN CORPORATION
SLDE SLIDE INS HLDG INC
Avalo Reports Second Quarter 2025 Financial Results and Recent Busines...
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, t...
CX360, Inc. Commends FCC Decision to Require SMS Georouting for the 98...
CX360, Inc. Commends FCC Decision to Require SMS Georouting for the 988 Suicide & Crisis Lifeline New decision ensures help seekers receive localized support across communication channels OMAHA, Neb., July 24, 2025 (GLOBE NEWSWIRE) -- CX360, Inc. (“”), a leader in AI-powered customer experience solutions and part of WestCX under the West Technology Group portfolio, applauds today’s decision by Chairman Carr and the Federal Communications Commission (FCC) to adopt new regulations requiring text providers to develop a system for georouting text messages to the . This decision builds on th...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences: HCW Annual Inflammation & Immunology Virtual ConferenceFireside ChatJune 30, 2025, at 11:00 am ET BTIG Virtual Biotechnology Conference 20251x1sJuly 29-30, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors secti...
Mosaicx Launches AI-Native CX Platform and Wins Top Honor at CCW Las V...
Mosaicx Launches AI-Native CX Platform and Wins Top Honor at CCW Las Vegas 2025 Recognized for innovation and inclusion, Mosaicx debuts next-generation Engage platform and earns Best Workplace for Gender Equity Award OMAHA, Neb., June 18, 2025 (GLOBE NEWSWIRE) -- , a leader in AI-powered customer experience solutions and part of WestCX under the West Technology Group portfolio, made a major impact at this year’s Customer Contact Week (CCW) in Las Vegas. The company unveiled a significant update to its flagship intelligent virtual agent platform, Engage, and was honored as CCWomen’s Best...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board o...
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. “We are pleased to welcome Dr. Jain to Avalo’s Board of Directors,” said Michael Heffernan, Chairman of the Board. “Rita’s extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biophar...
Mosaicx Unveils AI-Native CX Platform at CCW Las Vegas
Mosaicx Unveils AI-Native CX Platform at CCW Las Vegas CCW Award finalist and pioneer in native AI to lead three speaking sessions OMAHA, Neb., June 05, 2025 (GLOBE NEWSWIRE) -- , a pioneer in customer experience, today announced the launch of the next era of its product. The company will demo the next-generation AI-native platform at (CCW) in Las Vegas from June 9-12. Building on 30 years of CX experience, Mosaicx, part of WestCX, within the West Technology Group portfolio, brings to market a transformational leap in customer engagement, delivering intelligent, adaptive, and seamless...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.